KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Revenue: 2017-2025

Historic Revenue for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $1.0 billion.

  • Moderna's Revenue fell 45.44% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 55.50%. This contributed to the annual value of $3.2 billion for FY2024, which is 52.75% down from last year.
  • Latest data reveals that Moderna reported Revenue of $1.0 billion as of Q3 2025, which was up 615.49% from $142.0 million recorded in Q2 2025.
  • Moderna's Revenue's 5-year high stood at $7.2 billion during Q4 2021, with a 5-year trough of $108.0 million in Q1 2025.
  • For the 3-year period, Moderna's Revenue averaged around $1.0 billion, with its median value being $966.0 million (2024).
  • As far as peak fluctuations go, Moderna's Revenue spiked by 24,112.50% in 2021, and later crashed by 92.76% in 2023.
  • Moderna's Revenue (Quarterly) stood at $7.2 billion in 2021, then declined by 29.50% to $5.1 billion in 2022, then tumbled by 44.71% to $2.8 billion in 2023, then tumbled by 65.64% to $966.0 million in 2024, then tumbled by 45.44% to $1.0 billion in 2025.
  • Its Revenue was $1.0 billion in Q3 2025, compared to $142.0 million in Q2 2025 and $108.0 million in Q1 2025.